King Luther Capital Management Corp Makes New $2.24 Million Investment in TransMedics Group, Inc. $TMDX

King Luther Capital Management Corp bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 20,000 shares of the company’s stock, valued at approximately $2,244,000. King Luther Capital Management Corp owned 0.06% of TransMedics Group at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Marshall Wace LLP increased its holdings in TransMedics Group by 258.7% in the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after purchasing an additional 394,340 shares in the last quarter. Zevenbergen Capital Investments LLC boosted its position in shares of TransMedics Group by 112.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after buying an additional 136,995 shares during the period. Next Century Growth Investors LLC acquired a new stake in shares of TransMedics Group in the second quarter valued at about $16,049,000. Goldman Sachs Group Inc. grew its stake in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after buying an additional 86,721 shares in the last quarter. Finally, Renaissance Group LLC purchased a new stake in shares of TransMedics Group during the 3rd quarter valued at about $8,536,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of analyst reports. Canaccord Genuity Group upped their price target on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Needham & Company LLC raised their price target on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday, December 8th. Morgan Stanley boosted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Finally, Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $144.25.

Insider Buying and Selling

In other news, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares in the company, valued at approximately $2,103,235.68. This trade represents a 5.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Weill sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 8,920 shares of company stock worth $1,257,310. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Trading Up 1.0%

TMDX opened at $134.25 on Friday. TransMedics Group, Inc. has a 12-month low of $62.07 and a 12-month high of $156.00. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The stock has a market capitalization of $4.59 billion, a PE ratio of 54.35 and a beta of 2.06. The firm’s fifty day moving average price is $132.50 and its 200 day moving average price is $125.87.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.